Keros Therapeutics Inc (KROS)
$58.95
Insights on Keros Therapeutics Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 46.7% return, outperforming this stock by 4.7%
Performance
- $58.24$61.33$58.95
1.2%
Downside
Day's Volatility :5.04%
Upside
3.88%
- $27.02$73.00$58.95
54.16%
Downside
52 Weeks Volatility :62.99%
Upside
19.25%
Returns
| Period | Keros Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 14.29% | -0.7% | 0.0% |
6 Months | 106.37% | 6.6% | 0.0% |
1 Year | 41.96% | 3.7% | -1.5% |
3 Years | 15.13% | 14.0% | -21.8% |
Highlights
Market Capitalization | 2.1B |
Book Value | $10.43 |
Earnings Per Share (EPS) | -5.2 |
Wall Street Target Price | 88.88 |
Profit Margin | 0.0% |
Operating Margin TTM | -32486.01% |
Return On Assets TTM | -31.39% |
Return On Equity TTM | -50.19% |
Revenue TTM | 151.0K |
Revenue Per Share TTM | 0.01 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | -87.3M |
EBITDA | -169.1M |
Diluted Eps TTM | -5.2 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -5.27 |
EPS Estimate Next Year | -5.47 |
EPS Estimate Current Quarter | -1.37 |
EPS Estimate Next Quarter | -1.33 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 50.77%
Technicals Summary
Sell
Neutral
Buy
Keros Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Keros Therapeutics Inc | -7.19% | 106.37% | 41.96% | 15.13% | 15.13% |
 Moderna, Inc. | -0.79% | 20.27% | -27.48% | -36.11% | 359.53% |
 Regeneron Pharmaceuticals, Inc. | -6.12% | 9.1% | 11.53% | 80.35% | 170.35% |
 Novo Nordisk A/s | -6.29% | 23.82% | 46.7% | 242.59% | 414.69% |
 Vertex Pharmaceuticals Incorporated | -4.44% | 6.95% | 20.9% | 79.35% | 133.77% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Keros Therapeutics Inc | NA | NA | NA | -5.27 | -0.5 | -0.31 | NA | 10.43 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.71 | 25.71 | 1.46 | 45.13 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.58 | 46.58 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.42 | 28.42 | 0.53 | 16.73 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Keros Therapeutics Inc | Buy | $2.1B | 15.13% | NA | 0.0% |
Moderna, Inc. | Buy | $39.8B | 359.53% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.1B | 170.35% | 25.71 | 30.14% |
Novo Nordisk A/s | Buy | $551.2B | 414.69% | 46.58 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $101.9B | 133.77% | 28.42 | 36.68% |
Institutional Holdings
FMR Inc
10.77%BlackRock Inc
5.66%Alkeon Capital Management, LLC
4.17%Vanguard Group Inc
3.98%BRAIDWELL LP
3.77%Orbimed Advisors, LLC
3.53%
Corporate Announcements
Keros Therapeutics Inc Earnings
Keros Therapeutics Inc’s price-to-earnings ratio stands at None
Read More
Company Information
keros therapeutics, inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. the company's lead protein therapeutic product candidate is ker-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or mds, and in patients with myelofibrosis. it is also developing small molecule product candidate ker-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or fop, and is currently in a phase 1 clinical trial; and ker-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or pah. the company was founded i
Organization | Keros Therapeutics Inc |
Employees | 136 |
CEO | Dr. Jasbir S. Seehra Ph.D. |
Industry | Commercial Services |
Discover More
Endeavor Group Holdings, Inc.
$58.95
-0.54%
Associated Banc-corp
$58.95
-0.54%
Assetmark Financial Holdings Inc
$58.95
-0.54%
Essential Utilities Inc.
$58.95
-0.54%
Vanguard Ultra Short Bond Et
$58.95
-0.54%
Surgery Partners Inc
$58.95
-0.54%
Sl Green Realty Corp.
$58.95
-0.54%
Janus Henderson Mortgage-backed Securities Etf
$58.95
-0.54%
Goldman Sachs Activebeta Int
$58.95
-0.54%